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Age- and sex-dependent role of 
osteocytic pannexin1 on bone and 
muscle mass and strength
Alexandra Aguilar-perez1, Rafael pacheco-costa1, emily G. Atkinson1, padmini Deosthale1, 
Hannah M. Davis1, Alyson L. essex1, Julian e. Dilley  1, Leland Gomez1, Joseph e. Rupert4, 
teresa A. Zimmers  1,3,4,5, Roger J. thompson6, Matthew R. Allen1,2 & Lilian i. plotkin  1,2,3
Pannexins (Panxs), glycoproteins that oligomerize to form hemichannels on the cell membrane, are 
topologically similar to connexins, but do not form cell-to-cell gap junction channels. There are 3 
members of the family, 1–3, with Panx1 being the most abundant. All Panxs are expressed in bone, 
but their role in bone cell biology is not completely understood. We now report that osteocytic Panx1 
deletion (Panx1Δot) alters bone mass and strength in female mice. Bone mineral density after reaching 
skeletal maturity is higher in female Panx1Δot mice than in control Panx1fl/fl mice. further, osteocytic 
Panx1 deletion partially prevented aging effects on cortical bone structure and mechanical properties. 
Young 4-month-old female Panx1Δot mice exhibited increased lean body mass, even though pannexin 
levels in skeletal muscle were not affected; whereas no difference in lean body mass was detected 
in male mice. Furthermore, female Panx1-deficient mice exhibited increased muscle mass without 
changes in strength, whereas Panx1Δot males showed unchanged muscle mass and decreased in 
vivo maximum plantarflexion torque, indicating reduced muscle strength. Our results suggest that 
osteocytic Panx1 deletion increases bone mass in young and old female mice and muscle mass in young 
female mice, but has deleterious effects on muscle strength only in males.
Pannexin 1 (Panx1) is the most widespread member of the pannexin family of proteins and its mRNA expression 
has been detected in all bone cells1–3. Similar to connexins, Panx1 molecules associate to form hemichannels in 
the cell membrane, but unlike connexins, there is no evidence for the presence of pannexin channels linking 
neighboring cells4,5. Global Panx1-deficient mice have been generated and Panx1 deficiency does not alter can-
cellous bone structure in the distal femur, when compared to wild type mice6. However, fatigue loading-induced 
increased intracortical resorption observed in wild type is absent in Panx1-deficient mice6. Whether deletion of 
Panx1 alters bone mass or mechanical properties during aging has not been reported.
Panx1 channels are permeable to ATP and open in response to various stimuli including mechanical stress, 
Panx1 ligands, low oxygen concentration, increased K+ and intracellular calcium levels, and apoptosis7. In par-
ticular, activation of caspase-3 in apoptotic cells results in cleavage of the Panx1 auto-inhibitory C-terminus tail, 
irreversibly opening the channels8. Indeed, he increase in selective membrane permeability that occurs in the 
early stages of apoptosis has been ascribed to Panx1 channel opening. Small molecules are then released through 
Panx1 channels, including nucleotides. ATP, one such nucleotide, can then act as a chemotactic signal to recruit 
cells with phagocytic activity9.
Osteocytes, considered the main regulatory cells in bone, produce and release molecules that modulate the 
differentiation and activity of osteoblasts and osteoclasts, thereby controlling bone modeling and remodeling10. 
Further, apoptotic osteocytes are believed to recruit osteoclasts, leading to targeted bone resorption11. There is 
also evidence that osteocyte viability influences bone mechanical properties, with increased osteocyte apoptosis 
in conditions with increased bone fragility; conversely, reduced osteocyte apoptosis is associated with treatments 
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that increase bone mechanical properties12. More recently we have reported that apoptotic osteocytic cells release 
factors to the culture media (conditioned media) in vitro that stimulate osteoclastogenesis; and that prevention 
of osteocytic cell apoptosis reversed the increase in osteoclast formation induced by the conditioned media 
from osteocytic cells13. Further, there is higher osteoclast inducing activity in the conditioned medium of bones 
from old mice (21-months) than from young mice (4-months). Treating these bones with an apoptosis inhibitor 
reduced both apoptosis and osteoclast-inducing activity14. Taken together, these pieces of evidence suggest that 
osteocyte apoptosis leads to the release of osteoclastogenic factors. This led us to propose that, with aging and 
increased osteocyte apoptosis, Panx1 channels open and release factors that increase osteoclastogenesis and ulti-
mately, bone resorption.
To test the potential role of Panx1 channels in skeletal aging, we generated mice lacking Panx1 in cells express-
ing the 8 kb fragment of the DMP1 promoter, which we previously showed deletes genes preferentially from oste-
ocytes15–18. We found that Panx1 deletion has small but significant effects on bone mass that is more evident as 
the mice age. Further, absence of Panx1 prevented the increase in apoptosis-associated genes and the decrease in 
bone strength detected even in the relatively young 13-month-old mice. Unexpectedly, osteocytic Panx1 deletion 
augmented muscle mass in young female mice, but not in male mice, even though Panx1 was not deleted from 
skeletal muscle in our model. Our results suggest that osteocytic Panx1 can mediate the effect of osteocytes as 
regulators of bone and muscle mass in an age- and sex-dependent manner.
Results
Prevention of apoptosis and maintenance of bone mass in middle aged mice lacking Pannexin 
1 in osteocytes. We examined tissues from mice carrying the DMP1-8kb-Cre transgene and Panx1 floxed 
alleles (Panx1ΔOt mice) and littermate mice bearing only floxed Panx1 (Panx1fl/fl). Panx1 protein levels were 
decreased by 50% in calvaria bone from female Panx1ΔOt mice, compared to control Panx1fl/fl mice (Fig. 1A). 
Mice lacking Panx1 in osteocytes did not exhibit apparent anatomical abnormalities and qualitatively showed 
similar distribution of cartilage and mineralized bone at birth as Panx1fl/fl littermates (Fig. 1B). Aging resulted in 
increased mRNA expression of apoptosis-associated genes Foxo3, Cdkn1b/p27, and Ddit3/GADD153 in cortical 
bone preparations containing osteocytes from control Panx1fl/fl mice (Fig. 1C), consistent with the increase in 
TUNEL positive osteocytes documented in 14-month-old wild type mice19. Unexpectedly, deletion of Panx1 from 
osteocytes prevented the increase in all apoptosis-associated genes tested in female mice. However, since the gene 
expression analysis was performed using whole tissue, it is not possible to conclusively determine which cell type 
is undergoing apoptosis.
Longitudinal analysis of body weight showed no differences between genotypes in female mice up to 13 month 
of age (Fig. 1D). On the other hand, Panx1ΔOt mice exhibited higher total BMD (5.5%) at 12 months of age, 
compared to age- and sex-matched Panx1fl/fl littermate mice. Femoral BMD was higher (5.6–13.9%) at 12 and 13 
months of age in Panx1ΔOt compared to Panx1fl/fl littermates, and spinal BMD (3.2–5.1%) was higher starting at 
5 months of age.
We next examined the structural and cellular effects of Panx1 deletion in 4- and 13-month-old female mice. 
Four-month-old C57BL/6 mice are considered mature adults (equivalent to a 20/30-year-old human), whereas 
13-month-old mice are considered middle-aged (equivalent to 38/47-year-old human)20. We selected these 
two ages because there was a significant difference in BMD between those 2 ages in control mice, and a signifi-
cantly higher BMD in the Panx1ΔOt mice compared to Panx1fl/fl mice at 13 months. μCT analysis of the femoral 
mid-diaphysis revealed that aging resulted in a larger marrow cavity area, independent of Panx1 expression, lower 
cortical bone area/tissue area only in control Panx1fl/fl mice, and higher cortical thickness only in Panx1ΔOt mice 
(Fig. 2A). Panx1 deletion prevented the decrease in cortical bone area/tissue area and increased cortical thick-
ness in the femoral mid-diaphysis in the aged animals. In the lumbar vertebrae, the overall aging effect was only 
manifested by an increase in trabecular separation, independent of Panx1 (Fig. 2B). Further, aged Panx1ΔOt mice 
exhibit increased trabecular thickness compared to young Panx1ΔOt.
Improved mechanical properties in the absence of Panx1 in osteocytes. In control Panx1fl/fl 
female mice, mechanical testing of the femoral mid-diaphysis revealed a significant overall decrease in the struc-
tural mechanical displacement and work parameters as well as increased stiffness in 13-month-old compared to 
4-month-old female mice (Fig. 3A). In addition, we found an age-related effect on the material-level mechanical 
properties yield stress, toughness, modulus, and total strain, which were all significantly reduced (Fig. 3B). This 
evidence indicates that even though the 13-month-old are not considered “old”, there is a substantial deteriora-
tion of the cortical bone mechanical properties at both the structural and material level. Deletion of Panx1 in 
Panx1ΔOt mice preserved some of those properties, yield force, work to yield, and yield stress were only decreased 
in aged Panx1fl/fl mice, compared to 4-month-old mice of the same genotype. Further, deletion of Panx1 resulted 
in increased yield force, displacement to yield, work to yield, strain to yield and resilience in the Panx1ΔOt com-
pared to Panx1fl/fl mice at 13 months of age. On the other hand, modulus was only decreased in 13-month-old 
Panx1-deficient mice compared to mice of the same genotype at 4 months of age, and to Panx1fl/fl mice at 13 
months of age. This evidence suggests that the presence of Panx1 in osteocytes in aged mice is deleterious for bone 
biomechanical properties and that by deleting the gene; some mechanical properties are improved to levels that, 
in some cases, are similar to those of younger animals.
Osteocyte Pannexin depletion does not alter bone formation or osteoclast number/surface 
in young or aged mice. Consistent with our previous studies19, 13-month-old mice exhibited a decrease 
in mineral apposition rate and an increase in mineralizing surface on the periosteal surface of the femoral 
mid-diaphysis, the net effect being no difference in bone formation rate (Fig. 4A). Mineral apposition rate was 
also decreased on the endocortical surface of the femur, whereas mineralizing surface was not affected, resulting 
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in a decrease in bone formation rate in aged mice. In addition, osteoclast number and surface, as well as eroded 
surface were all increased on the endocortical surface of aged mice, independently of whether they express Panx1 
or not (Fig. 4B). Two-way-ANOVA analysis of the parameters revealed no effect of genotype and no age-genotype 
interactions (Table 1). Our data suggests that overall; deletion of Panx1 from osteocytes did not alter histomor-
phometric parameters in the cortical bone of the femoral mid-diaphysis.
Aging also led to changes in dynamic and static histomorphometry in the cancellous bone of the lumbar 
vertebrae (Fig. 5). Specifically, mineral apposition rate and bone formation rate were decreased in 13-month-old 
mice (Fig. 5A). Further, osteoclast and eroded surface (Fig. 5B) and osteoblast number and surface (Fig. 5C) were 
decreased in 13-month-old mice compared to 4-month-old mice, independently of Panx1 expression. Consistent 
with the decrease in osteoblast number and surface, the levels of the circulating markers of bone formation P1NP 
and alkaline phosphatase were decreased in 13-month-old mice of both genotypes, compared to young mice 
(Fig. 5D). Conversely, deletion of Panx1 led to a significant increase in bone formation rate in young mice and a 
decrease in osteoclast surface in aged mice (Fig. 5A,B), without altering the circulating levels of bone formation 
markers (Fig. 5D). The discrepancies between bone formation measured by dynamic histomorphometry and 
circulating markers are likely due to the fact that whereas histomorphometry assess the local activity of the osteo-
blasts, the circulating parameters reflect changes in the whole animal. Indeed, whereas we found increase in MAR 
and BFR in young pannexin deficient mice in cancellous bone, these parameters were not changed in cortical 
bone. This lack of higher osteoblast activity in the cortical compartment could have diluted the P1NP and ALP 
produced by cancellous bone osteoblasts, present in the circulation.
Figure 1. Deletion of Panx1 in osteocytes increases bone mass. (A) Panx1 protein levels in calvaria bones from 
Panx1fl/fl and Panx1Δot mice at 4 months of age were assessed by Western blotting and β-actin was used as a 
loading control. (B) Representative images of whole body histological preparations (n = 3/genotype) stained by 
Alcian blue/alizarin red in 6-day-old mice for visual inspection of cartilage (blue) and calcified tissue (magenta). 
(C) The levels of the apoptosis-related genes were measured by qPCR bone marrow-flushed long bones obtained 
from female mice. Bars represent mean ± s.d., #p < 0.05 versus Panx1fl/fl mice at the same age, *p < 0.05 versus 
4-month-old mice of the same genotype, and lines indicate age effect, by 2-way ANOVA. (D) Body weight and 
total body, spinal and femoral BMD were assessed monthly in female mice from 1 to 13 months of age by DXA 
(n = 9–12 per group). ¥p < 0.05 versus Panx1fl/fl mice at the same age by t-test.
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Reduced expression of osteoclastic genes in bones from aged Panx1Δot mice. We then exam-
ined whether changes in the expression of osteoclast-related genes could explain the histomorphometric changes 
observed in aged mice. Although there was a genotype effect on the mRNA levels of Itgam (CD11b), an osteoclast 
precursor marker, post-hoc analysis only showed a significant decrease in CD11b levels in bone marrow cells 
from aged Panx1ΔOt mice (Fig. 6A), suggesting that deletion of osteocytic Panx1 could lead to a depletion of 
osteoclast precursors. Further, analysis of cortical bone preparations (without the bone marrow) showed that 
the levels of Tnfsf11, the gene that encodes for the pro-osteoclastogenic cytokine RANKL, and Tnfrsf11b, the 
gene that encodes for OPG. a RANKL decoy receptor that inhibits osteoclastogenesis, were increased in corti-
cal bone of aged Panx1fl/fl mice compared to young animals, resulting in no change in the RANKL/OPG ratio 
(Fig. 6B). Further, RANKL and OPG levels were significantly decreased in aged Panx1ΔOt mice compared to 
controls at the same age. However, since both RANKL and OPG were decreased, there were no changes in the 
RANKL/OPG ratio between mice of the two genotypes at 13 months of age, whereas the ratio was lower in the 
Panx1ΔOt aged compared to young mice. Further, 13-month-aged Panx1fl/fl mice showed higher mRNA levels for 
tartrate-resistant acid phosphatase (TRAP), an enzyme produced by osteoclasts, and both control and Panx1ΔOt 
mice showed increased levels of the osteoclastic genes DCSTAMP (dendritic cell-specific transmembrane pro-
tein) and NFATC1 (Nuclear factor of activated T-cells, cytoplasmic 1) mRNA compared to young mice. Deletion 
of Panx1 led to a decrease in these genes in 13-month-old Panx1ΔOt compared to Panx1fl/fl mice (Fig. 6C). This 
evidence suggests that a potential beneficial effect of Panx1 deletion due to reduced osteoclast number/activity 
might be obtained in older animals. However, while we could detect an effect at the gene expression level, the 
number of osteoclasts or the eroded surface were not altered by Panx1 deletion in cortical bone (Fig. 4B).
Panx1 deletion results in increased lean and muscle mass in female, but not male mice. Further 
analysis of the serial DXA measurement (Fig. 1D) showed a transient increase in total lean body mass of approx-
imately 7% in female Panx1ΔOt compared to Panx1fl/fl mice at 3 and 4 month of age, which was lost by 5 months 
of age (not shown). We next generated a separate set of mice in order to confirm these changes, and to determine 
whether male mice also exhibited changes in bone or lean body mass. Mice were analyzed at 10-weeks of age, 
and the increase in lean body mass was reproduced in female mice, but was not detected in male mice (Fig. 7A). 
Further, the percent fat mass was only decreased in female mice (Fig. 7B). Similar results were obtained when 
lean mass was calculated as percentage of total tissue mass (Fig. 7C). We also detected an increase in total BMD in 
this new cohort of female mice, but not in the males (Fig. 7D). Because muscle is the main component of the lean 
body mass, and reporter mice revealed that DMP1–8kb-Cre is expressed in skeletal muscle21, we then measured 
Panx1 mRNA and protein levels in tibialis anterior and found no differences between control and Panx1-deficient 
mice (Fig. 7E).
The individual weights of the tibialis anterior, soleus, gastrocnemius and extensor digitorum longus (EDL) 
muscles were higher in male than in female mice, as expected, but the muscle mass was not altered by osteocytic 
Panx1 deletion in the males. Further, the weight of the tibialis anterior, gastrocnemius and EDL muscles corrected 
by tibia length was not different between genotypes for either sex, with only a tendency towards increase in the 
Figure 2. Osteocytic Panx1 removal preserves cortical bone volume and increases cortical thickness in aged 
female mice. (A) Femur cortical bone geometry in the mid-diaphysis was assessed by µCT (n = 9–12 per group). 
(B) Analysis of cancellous bone microarchitecture in L5 vertebra was assessed by µCT (n = 9–12 per group). 
Bars represent mean ± s.d., #p < 0.05 versus Panx1fl/fl mice at the same age, *p < 0.05 versus 4-month-old mice 
of the same genotype, and lines indicate age effect, by 2-way ANOVA.
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weight of the gastrocnemius in female mice. However, the soleus muscle weighed 21% more (Fig. 8A) and its 
cross-sectional area was 38% higher (Fig. 8B) in female Panx1ΔOt compared to control littermates.
We next examined muscle function by conducting an in vivo contractility test. To our surprise, we found that 
whereas deletion of Panx1 in female mice did not alter muscle contractility, there was a significant decrease in 
this parameter in male mice, consistent with Panx1ΔOt male muscles contracting with lower forces than those of 
control mice (Fig. 8C). Thus, our data suggests that Panx1 from osteocytes may have a role in skeletal muscle mass 
and strength, which differs in male versus female mice.
Figure 3. Aged Panx1Δot female mice have increased mechanical properties in cortical bone. Femur cortical 
bone structural (A) and material (B) mechanical properties were measured by 3-point bending at 4 and 13 
months of age female mice. (n = 9–12 per group). Bars represent mean ± s.d., #p < 0.05 versus Panx1fl/fl mice at 
the same age, *p < 0.05 versus 4-month-old mice of the same genotype, and lines indicate age effect, by 2-way 
ANOVA.
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Discussion
In this study, using a model of conditional Panx1 deletion in osteocytes, we first characterized the contribu-
tion of osteocytic Panx1 channels to the adult skeleton. We found that Panx1 deletion resulted in higher bone 
mass and strength in aged female mice. Removal of Panx1 also reversed the increase in apoptosis-related genes 
in the 13-month-old mice adding further support to the association between osteocyte apoptosis and reduced 
bone strength. However, the mechanism that mediates the pro-apoptotic effect of Panx1 channels remains to be 
determined.
We also found an unexpected effect of Panx1 deletion on lean and muscle mass that was detected only in 
females, even though Panx1 levels were not changed in skeletal muscle from Panx1ΔOt mice. While there was 
an overall increase in lean mass in females, only the soleus showed an increase in weight with a corresponding 
increase in myofiber area. The reason why osteocyte Panx1 function appears to be muscle group specific is pres-
ently unknown, but it could involve specific effects on slow contracting muscles like the soleus versus fast con-
tracting muscles such as the EDL, tibialis anterior, and gastrocnemius muscles. This evidence raises the possibility 
that osteocytes release factors through Panx1 channels that restrain skeletal muscle development in female mice, 
Figure 4. Panx1 deletion does not alter bone formation or osteoclast number/surface in cortical bone from 
female mice. (A) Periosteal (Ps) and endocortical (Ec) MS/BS, MAR, and BFR/BS were measured in unstained 
femoral cross-sections (n = 9–12 per group). (B) N.Oc/BS, Oc.S/BS, ES/BS were scored on the endocortical 
surface of the femoral mid-diaphysis after staining for TRAPase/Toluidine blue in Panx1fl/fl and Panx1Δot mice 
at 4 and 13 months of age (n = 9–12 per group). Bars represent mean ± s.d., Lines indicate age effect, by 2-way 
ANOVA.
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Figure endpoint
p value
age genotype
age x 
genotype
1C
FoxO3 mRNA 0.002 0.443 0.004
p27 0.017 0.166 <0.001
GADD153 <0.001 0.007 0.079
2A
marrow cavity area <0.001 0.417 0.506
BA/TA <0.001 0.060 0.067
cortical thickness 0.309 0.006 0.055
2B
BV/TV 0.074 0.436 1.891
Tb.Th 0.030 0.281 0.548
Tb.N 0.747 0.505 0.479
Tb.Sp 0.044 0.590 0.576
3A
yield force 0.145 0.020 0.029
displacement to yield <0.001 0.015 0.039
work to yield 0.002 0.030 0.052
stiffness <0.001 0.862 0.895
post-yield displacement <0.001 0.796 0.521
total displacement <0.001 0.954 0.718
ultimate force 0.072 0.933 0.987
total work <0.001 0.841 0.396
post-yield work <0.001 0.468 0.170
3B
yield stress 0.005 0.800 0.100
strain to yield 0.419 0.010 0.009
toughness <0.001 0.124 0.682
modulus <0.001 0.006 0.289
total strain <0.001 0.908 0.837
resilience 0.441 0.210 0.037
ultimate stress 0.508 0.080 0.576
4A
Ps MAR <0.001 0.607 0.163
Ps MS/BS <0.001 0.563 0.819
Ps BFR/BS 0.352 0.740 0.342
Ec MAR 0.017 0.929 0.757
Ec MS/BS 0.085 0.676 0.112
Ec BFR/BS 0.025 0.751 0.257
4B
Oc.N/B.Pm <0.001 0.023 0.993
Oc.S/BS <0.001 0.127 0.654
ES/BS <0.001 0.119 0.826
5A
MAR <0.001 0.003 0.110
MS/BS 0.958 0.638 0.141
BFR/BS <0.001 0.012 0.205
5B
Oc.N/B.Pm 0.814 0.108 0.017
Oc.S/BS <0.001 0.159 0.764
ES/BS <0.001 0.246 0.439
5C
N.Ob/BPm <0.001 0.363 0.808
Ob.S/BS <0.001 0.345 0.742
5D
P1NP <0.001 0.182 0.239
ALP 0.001 0.433 0.806
6A CD11b 0.666 0.021 0.207
6B
Rankl 0.002 0.027 0.002
OPG <0.001 0.214 0.059
Rankl/OPG 0.001 0.786 0.787
6C
TRAP 0.060 0.110 0.007
DCSTAMP <0.001 0.014 0.004
NFATC1 <0.001 0.052 0.032
Table 1. p values for age, genotype, and their interaction by 2-way ANOVA.
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or that such factors induce subsequent sex-specific events on other pathways or cell types that have the same 
effect. However, muscle function was not altered by Panx1 deletion in female mice, whereas it was deteriorated 
in male mice lacking Panx1. This evidence adds to the growing body of research showing that first, osteocytes are 
able to release molecules that affect skeletal muscle mass and function22, and second, that “female” and “male” 
osteocytes behave differently. Potential factors involved in this bone-muscle interaction are small molecules such 
as ATP, prostaglandin E2, or nitric oxide, which could be released through Panx1 channels and, therefore, directly 
impacted by the reduction in Panx1 protein levels; and osteocalcin or TGFβ, bone cell-produced factors known to 
alter skeletal muscle mass and function and which expression could be indirectly affected by reduction in Panx1 
expression or channel function. Further studies are required to identify the osteocyte factors that control skeletal 
muscle mass and strength, and the mechanisms by which Panx1 channels regulate the expression or release of 
such factor(s) in a sex- and muscle group-specific fashion. Furthermore, we will investigate whether the sex dif-
ferences are maintained as the mice age.
The role of pannexin channels in bone is beginning to be revealed23. A previous report showed that mice in 
which Panx1 levels are reduced by 70% in all tissues do not exhibit intra-cortical resorption following fatigue 
loading, even in the presence of apoptotic osteocytes6, suggesting that opened Panx1 channels provide signals 
that recruit osteoclasts. However, unlike our study in which osteocytic Panx1 deletion led to small, but significant 
changes in cortical bone structure at 13 months of age, ubiquitous reduction of Panx1 did not result in a pheno-
type in cortical or cancellous bone in 4–5-month old female mice. Taken together with the current study, these 
pieces of evidence suggest that the role of Panx1 restraining bone accrual is only apparent as the mice become 
older or when they are physiologically challenged.
Extracellular ATP induces osteoclast precursor commitment and differentiation into mature cells24–26. Thus, 
reduction of Panx1-mediated osteocyte ATP release could explain the decrease in expression of osteoclastic 
genes in cortical bone, and the reduced number of osteoclast progenitors in the bone marrow observed in aged 
Panx1ΔOt mice in our study. This evidence suggests an innate, reduced ability to form osteoclasts in the absence 
Figure 5. Panx1Δot female mice exhibited minimal changes in vertebral dynamic and static histomorphometric 
parameters. (A) MS/BS, MAR, and BFR/BS were measure in unstained sections of lumbar vertebra (n = 9–12 
per group). (B) N.Oc/BS, Oc.S/BS, ES/BS were scored in vertebral cancellous bone after staining for TRAPase/
Toluidine blue in Panx1fl/fl and Panx1Δot mice at 4 and 13 months of age (n = 9–12 per group). (C) N.Ob/BS and 
Ob.S/BS were scored in lumbar vertebra stained with von Kossa/McNeal (n = 9–12 per group). (D) Circulating 
markers of bone formation (P1NP, 9–12 per group and ALP, n = 9–12 per group) were measured in serum by 
ELISA. Bars represent mean ± s.d., #p < 0.05 versus Panx1fl/fl mice at the same age, and lines indicate age effect, 
by 2-way ANOVA.
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of the channel, as also evidenced by lower fusion of macrophages (which originate from the same precursors as 
osteoclasts) in cells derived from Panx1 null mice27. However, although we found an increase in osteoclast num-
ber on the endocortical surface of the femur in the aged Panx1fl/fl mice consistent with the increased expression 
of the osteoclastic genes in these mice, the reduced expression of these genes in the 13-month-old Panx1ΔOt 
mice did not translate into changes in osteoclast number on the endocortical surface of the femora (Fig. 4B). 
This potential discrepancy between gene expression and histomorphometry measurements for osteoclasts in 
aged mice could be due to the fact that bone preparations used for gene expression might include a combination 
of cortical and cancellous (in which osteoclast number was decreased, see Fig. 5B) bone. Further, whereas gene 
expression is corrected by cell number (reflected by the housekeeping gene levels), histomorphometric param-
eters are corrected by bone surfaces. Another apparent inconsistency is the fact that osteoclast number but not 
surface, was decreased in cancellous bone. This data suggests that while less osteoclasts are being generated (or 
more are dying) resulting in lower number of osteoclasts, the ones found on the bone surface are able to spread 
more, maintaining the percentage of the bone surface covered by osteoclasts similar to that of control littermates. 
Future studies are needed to determine whether deletion of osteocytic Panx1 increases the ability of osteoclasts to 
attach to the bone surface. Further, it remains possible that older mice must be used in order to detect a reduction 
in osteoclast numbers/surface in the absence of Panx1 in osteocytes.
Even though Panx1 deletion has a small effect on femoral cortical bone structure, reversing the decrease in 
bone area and increasing cortical thickness in the aged mice, a more profound effect of the deletion was found in 
the mechanical properties of the cortical bone of the femoral mid-diaphysis. Thus, aging induced the expected 
reduction in both structural and material bone mechanical properties, and deletion of Panx1 was able to reverse 
the decrease in yield force, displacement to yield, work to yield, yield stress, while increasing strain to yield and 
resilience. This pattern of differences, most of which are confined to the elastic portion of the mechanical test 
curve, point to the effects being in the mineral fraction of the tissue (as opposed to the organic/collagen por-
tion)28. This evidence, together with the reversal of the increased expression of apoptosis-related genes, adds 
further support for a role of osteocyte viability in the maintenance of bone mechanical properties. Future studies 
are needed to further our understanding on the link between osteocyte apoptosis and reduced bone strength.
In summary, our studies suggest previously unrecognized roles of osteocytic Panx1 channels on bone and 
skeletal muscle. Further, our data suggests that osteocytic Panx1 exerts a role in bone remodeling rather than 
modeling, affecting bone structure and strength with aging rather than during development. The evidence of the 
current report raises the possibility of using Panx1 channel inhibitors to ameliorate the deleterious effects of aging 
in the skeleton.
Methods
Mice. Mice with conditional deletion of Panx1 preferentially in osteocytes were generated by breeding Panx1fl/fl 
mice, provided by Roger J. Thompson (University of Calgary, Calgary, Canada), with mice harboring DMP1-
8kb-Cre18 in order to obtain homozygous Panx1fl/fl; DMP1-8kb-Cre mice (Panx1Δot). Mice were fed with regular 
diet and water ad libitum, and maintained on a 12 h light/dark cycle. The animal protocol was approved by the 
Institutional Animal Care and Use Committee of Indiana University School of Medicine, and animal care was 
Figure 6. Deletion of Panx1 in osteocytes decreases osteoclastic gene expression in aged 13-month-old female 
mice. (A) CD11b mRNA levels were measured in non-adherent bone marrow cells by qPCR and corrected by 
GAPDH (n = 9–12 per group). (B–D) mRNA levels of RANKL and OPG as well as the indicated osteoclast-
related genes were measured in bone marrow-flushed long bones by qPCR and corrected by GAPDH (n = 9–12 
per group). Bars represent mean ± s.d., #p < 0.05 versus Panx1fl/fl mice at the same age, *p < 0.05 versus 
4-month-old mice of the same genotype, and lines indicate age effect, by 2-way ANOVA.
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carried out in accordance with institutional guidelines. All studies were conducted in compliance with Public 
Health Service (PHS) policy, The Animal Welfare Act, “The Guide for the Care and Use of Laboratory Animals”, 
and other applicable University policies and procedures.
Whole-mount skeletal staining. Cartilage and mineralized tissue were analyzed in 6-day old newborn 
mice using alizarin red/alcian blue staining, as previously published29.
Western Blotting analysis. Calvaria protein lysates were prepared as described30 with the addition of 1x 
Halt protease inhibitor cocktail (Thermo Fisher Scientific In., Rockford, IL, USA, cat.#78430) to the lysis buffer. 
Next, 80 µg of protein were separated on 10% SDS-PAGE gels (GenScript, Piscataway, NJ, USA) and electrotrans-
ferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad Laboratories Inc., Hercules, CA, USA, cat.# 
1704157). Membranes were incubated in blocking solution (5% non-fat milk) for 1 hour and probed with primary 
antibodies in 5% non-fat milk against polyclonal anti-Panx1 (1:100, HPA016930) or anti-β-actin (1:1000, A5316) 
(Sigma-Aldrich, Saint Louis, MO, USA) overnight at 4 °C. Next day, membranes were incubated with secondary 
antibodies conjugated with horseradish peroxidase 1:10000 in 5% non-fat milk (Santa Cruz Biotechnology, Santa 
Cruz, CA, USA) for 1 hour at room temperature. After rinsing with TBS-Tween, the membranes were exposed to 
an enhanced chemiluminescence Western blotting substrate kit (Pierce Biotechnology Inc., Rockford, IL, USA).
RNA extraction and real-time PCR (qPCR). RNA isolation and reverse transcription from 
marrow-flushed whole bone or bone marrow cells were performed with TRIzol (Invitrogen, Grand Island, NY, 
USA) and cDNA kit (Applied Biosystems, Foster City, CA, USA), respectively19. Gene Expression Assay Mix 
TaqMan Universal Master Mix and an ABI 7900HT real-time PCR system were used for qPCR. Probes and 
primers were commercially available (Applied Biosystems, Foster City, CA, USA) or were designed using the 
Assay Design Center (Roche Applied Science, Indianapolis, IN, USA). Glyceraldehyde 3-phosphate dehydroge-
nase (GAPDH) was used as the house-keeping gene. Relative expression was determined using the ∆Ct method29.
Figure 7. Panx1Δot female mice exhibit increased muscle mass. (A–D) Body weight (A), total lean body mass 
(B), percent of lean and fat mass (C), and BMD (D) were measured in 10-week-old female and male mice by 
DXA (Piximus) (n = 9–13 per group). (E) mRNA and protein Panx1 levels were measured in tibialis anterior 
(TA) muscles by qPCR (corrected by GAPDH, n = 9 and 12 per group), and Western blotting (corrected by 
β-actin, n = 4 and 3), respectively. Bars represent mean ± s.d., *p < 0.05 versus Panx1fl/fl mice of the same sex, by 
2-way ANOVA.
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Bone mineral density (BMD) by dual energy x-ray absorptiometry (DXA). BMD measurements 
were performed by DXA using a PIXImus densitometer (G.E. Medical Systems, Lunar Division, Madison, WI, 
USA)31. Measurements included whole body BMD (total BMD, excluding the head and tail), entire femur (fem-
oral BMD) and L1-L6 vertebrae (spinal BMD), fat percentage (total fat body mass (g)/tissue total mass) and lean 
percentage (total lean body mass (g)/tissue total mass). Calibration was performed before scanning with a stand-
ard phantom as recommended by the manufacturer.
Micro-computed tomography (μct) analysis. Femora and lumbar vertebrae (L5) were dissected, 
cleaned of soft tissue, wrapped in PBS-soaked gauze and frozen at −20 °C until imaging31. Bones were scanned at 
9 μm resolution on a Skyscan 1176 (SkyScan, Kontich, Belgium) following standard procedures, and the recom-
mended nomenclature, symbols, and units32.
Bone histomorphometry. Histomorphometric analysis was performed in femora and lumbar ver-
tebrae (1–3) as previously described31. Mice were injected with calcein (30 mg/kg) and Alizarin Red (50 mg/
kg) (Sigma Chemical Co, St. Louis, MO, USA), 7 and 2 days before sacrifice, respectively. Dissected tissue was 
fixed in 10% neutral buffered formalin and processed at the ICMH Histology and Histomorphometry Core. 
Dynamic histomorphometric analysis was performed on methyl methacrylate embedded unstained femoral 
mid-diaphysis cross-sections and L1-L3 vertebral longitudinal bone sections using an epifluorescence micro-
scope. Static histomorphometric analysis was performed on TRAPase/Toluidine blue and von Kossa/McNeal 
stained-sections to visualize osteoclasts and osteoblasts, respectively. Histomorphometric analysis was performed 
using OsteoMeasure high resolution digital video system (OsteoMetrics Inc., Decatur, GA, USA) using units rec-
ommended by the Histomorphometry Nomenclature Committee of the American Society for Bone and Mineral 
Research (ASBMR)33.
Biomechanical testing. Biomechanical properties were assessed by femoral three-point bending testing 
following previously published protocols31. Briefly, bones were thawed to room temperature and hydrated in 0.9% 
saline. Femurs were loaded to failure at 2 mm/min with force versus displacement data collected at 10 Hz using a 
servo-hydraulic test system (TestResources Inc., Shakopee, MN, USA). Material-level properties were determined 
using μCT anterior–posterior diameter and cross-sectional moment of inertia, as previously described19.
In vivo muscle test. In vivo muscle strength was measured using the 1305A Whole Mouse/Rat Test 
System, Aurora Scientific Inc., Aurora, ON, Canada34. Data was recorded using the Dynamic Muscle Control/
Data Acquisition (DMC) and Dynamic Muscle Control Data Analysis (DMA) programs (Aurora Scientific Inc., 
Aurora, ON, Canada).
Figure 8. Increased muscle mass in female and decreased muscle strength in male mice lacking Panx1 in 
osteocytes. (A) Muscle weights normalized by tibia length were measured in 10-week old mice (n = 9–12 per 
group). TA: tibialis anterior, Sol: soleus, GA: gastrocnemius, EDL: extensor digitorum longus muscles. (B) 
Soleus physiological cross-sectional area was calculated [CSA = muscle mass (mg)/[(optimal length) × (fiber to 
muscle length ratio = 0.72) × (density of muscle = 1.06 mg/mm3)]. (C) In vivo assessment of maximum force in 
males and females (n = 9–13 per group). *p < 0.05 versus Panx1fl/fl mice of the same sex, by t-test.
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Statistical analysis. Data were analyzed by using SigmaPlot 13.0 (Systat Software Inc., San Jose, CA, 
USA). All data were evaluated by t-test or by 2-way ANOVA (Tukey post-hoc test), and values reported as the 
mean ± standard deviation (s.d.). Table 1 shows the p values for the sex and genotype effects and their interaction. 
Differences of p ≤ 0.05 were considered significant.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding 
author on reasonable request.
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